Indications for: MYOBLOC
Cervical dystonia, to reduce severity of abnormal head position and neck pain. Chronic sialorrhea.
Should be administered and managed by experienced physicians. Individualize. Cervical dystonia (treatment-experienced): initially 2500–5000 Units divided among affected muscles; (treatment-naïve): use lower initial dose. Sialorrhea: 1500–3500 Units divided among the parotid (500–1500 Units/gland) and submandibular (250 Units/gland) glands. May repeat treatments no sooner than every 12 weeks. Both: adjust subsequent doses based on response.
Infection at proposed inj site.
Distant spread of toxin effect.
Not interchangeable with other botulinum toxin products. Risk of distant spread of toxin effect (esp. in children treated for spasticity); see full labeling. Pre-existing dysphagia or breathing difficulties. Neuromuscular disorders (eg, myasthenia gravis, ALS, Lambert-Eaton syndrome); monitor closely. Compromised respiratory function; monitor. Contains human albumin; monitor for possible viral disease or Creutzfeldt-Jakob disease transmission. Pregnancy. Nursing mothers.
May be potentiated by aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds). May potentiate anticholinergic effects with concomitant anticholinergic drugs. Concomitant other botulinum toxin products or muscle relaxants may potentiate neuromuscular weakness.
Dry mouth, dysphagia (may be severe), inj site pain, headache; hypersensitivity reactions (discontinue if occur), possible antibody formation.
Generic Drug Availability: